Cushing's Syndrome - Market Insights, Epidemiology and Market Forecast - 2023 - Product Image

Cushing's Syndrome - Market Insights, Epidemiology and Market Forecast - 2023

  • ID: 4300712
  • Drug Pipelines
  • Region: Global
  • 56 Pages
  • DelveInsight
1 of 3
Cushing Syndrome - Market Insights, Epidemiology and Market Forecast - 2023 - 7MM reports provides an overview of the disease and global market size of the Cushing Syndrome for the 7MM. It also includes global historical and forecasted epidemiological data for the diagnosed prevalent cases of Cushing Syndrome from 2010-2023. According to Publisher, the forecasted patient population of Cushing Syndrome will increase at a CAGR of XX% from 2013 to 2023 and the worldwide Cushing Syndrome market is estimated to be USD XX Million by 2023. Cushing’s syndrome, also known as hypercortisolism is an endocrine disorder that occurs due to abnormally high levels of the hormone cortisol production in the body.

Types of Cushing Syndrome:
  • Exogenous Cushing’s Syndrome
  • Endogenous Cushing’s Syndrome
  • ACTH Dependent Cushing’s Syndrome
  • ACTH Independent Cushing’s Syndrome
Scope:
  • report covers the disease overview including pathophysiology, symptoms, diagnosis, disease management, and current treatment options.
  • Marketed information including available prescription drugs, its patent and exclusivity details.
  • The report also covers the detailed global historical and forecasted epidemiological data covering 7MM from 2010-2023.
  • It also provides Market size of Cushing Syndrome for 7MM from 2013 and forecasted Market size to 2023.
Note: Please allow up to 24 hours for delivery after payment has been made.
Note: Product cover images may vary from those shown
2 of 3
Report Introduction
Cushing's Syndrome Market Overview at a Glance
Total Market Size of Cushing's Syndrome for 7 MM in 2013-2023
Total Market Share Distribution of Cushing's Syndrome for 7 MM in 2015
Total Market Share Distribution of Cushing's Syndrome for 7 MM in 2023
Cushing's Syndrome
Overview
Types of Cushing's Syndrome
Symptoms
Causes
Pathophysiology
Diagnosis
Treatment
First Line of Treatment
Second Line of Treatment
Epidemiology and Patient Population
United States
Diagnosed Cases of Cushing's Syndrome in United States
Germany
Diagnosed Cases of Cushing's Syndrome in Germany
France
Diagnosed Cases of Cushing's Syndrome in France
United Kingdom
Diagnosed Cases of Cushing's Syndrome in United Kingdom
Spain
Diagnosed Cases of Cushing's Syndrome in Spain
Italy
Diagnosed Cases of Cushing's Syndrome in Italy
Japan
Diagnosed Cases of Cushing's Syndrome in Japan
Marketed Drugs
Korlym: Corcept Therapeutics
  • Drug Description
  • Mechanism of Action
  • Regulatory Milestones
  • Advantages & Disadvantages
  • Safety and Efficacy of Korlym
Signifor: Novartis Pharma K.K.
  • Drug Description
  • Mechanism of Action
  • Regulatory Milestones
  • Advantages & Disadvantages
  • Safety and Efficacy of Signifor
  • Product Profile
Ketoconazole HRA: Astorg
  • Drug Description
  • Mechanism of Action
  • Regulatory Milestones
  • Advantages & Disadvantages
  • Safety and Efficacy of Ketoconazole HRA
  • Product Profile
Metopirone: Astorg
  • Drug Description
  • Mechanism of Action
  • Regulatory Milestones
  • Advantages & Disadvantages
  • Product Profile
Cytadren: Novartis
  • Drug Description
  • Mechanism of Action
  • Regulatory Milestones
  • Advantages & Disadvantages
  • Product Profile
  • Emerging Therapies
Levoketoconazole: Strongbridge Biopharma Plc
  • Regulatory Milestones
  • Advantages & Disadvantages
  • Product Profile
  • Clinical Development
  • Clinical Pipeline Activity
  • Ongoing Trials Information
  • Clinical Trial by Phase
LCI699: Novartis
  • Advantages & Disadvantages
  • Product Profile
  • Clinical Development
  • Clinical Pipeline Activity
Signifor LAR: Novartis
  • Advantages & Disadvantages
  • Product Profile
  • Clinical Development
  • Clinical Pipeline Activity
  • Ongoing Trials Information
  • Clinical Trial by Phase
Metopirone: Astorg
  • Drug Description
  • Regulatory Milestones
  • Advantages & Disadvantages
  • Product Profile
  • Clinical Development
  • Ongoing Trials Information
  • Clinical Trial by Phase
Global Cushing's Syndrome: Country-Wise Market Analysis
Overview on Total Cushing's Syndrome Market (2015)
Overview on Total Cushing's Syndrome Market (2023)
United States Market Size
Europe Market Size
United Kingdom Market Size
Germany Market Size
France Market Size
Italy Market Size
Spain Market Size
Japan Market Size
Market Drivers
Market Restraints
Appendix
Report Methodology
Consulting Services
Disclaimer

List of Tables
Table 1: Diagnosed Cases Cushing's Syndrome in United States (2010-2023)
Table 2: Diagnosed Cases Cushing's Syndrome in Germany (2010-2023)
Table 3: Diagnosed Cases Cushing's Syndrome in France (2010-2023)
Table 4: Diagnosed Cases Cushing's Syndrome in United Kingdom (2010-2023)
Table 5: Diagnosed Cases Cushing's Syndrome in Spain (2010-2023)
Table 6: Diagnosed Cases Cushing's Syndrome in Italy (2010-2023)
Table 7: Diagnosed Cases Cushing's Syndrome in Japan (2010-2023)
Table 8: Levoketoconazole, Clinical Trials by Zone, 2016
Table 9: Clinical Trials by Trial status, 2016
Table 10: LCI699, Clinical Trials by Zone, 2016
Table 11: Clinical Trials by Trial status, 2016
Table 12: Signifor LAR, Clinical Trials by Zone, 2016
Table 13: Clinical Trials by Trial status, 2016
Table 14: Clinical Trials by Trial status, 2016
Table 15: United States Market Size of Cushing's Syndrome in USD, Million (2013-2023)
Table 16: United Kingdom Market Size of Cushing's Syndrome in USD, Million (2013-2023)
Table 17: Germany Market Size of Cushing's Syndrome in USD, Million (2013-2023)
Table 18: France Market Size of Cushing's Syndrome in USD, Million (2013-2023)
Table 19: Italy Market Size of Cushing's Syndrome in USD, Million (2013-2023)
Table 20: Spain Market Size of Cushing's Syndrome in USD, Million (2013-2023)

List of Figures
Figure 1: Normal Cortisol production mechanism/Pathway 12
Figure 2: Differential Diagnosis of Cushing's Syndrome 13
Figure 3: Diagnosed Cases of Cushing's Syndrome in United States (2010-2023) 16
Figure 4: Diagnosed Cases of Cushing's Syndrome in Germany (2010-2023) 17
Figure 5: Diagnosed Cases of Cushing's Syndrome in France (2010-2023) 18
Figure 6: Diagnosed Cases of Cushing's Syndrome in United Kingdom (2010-2023) 19
Figure 7: Diagnosed Cases of Cushing's Syndrome in Spain (2010-2023) 20
Figure 8: Diagnosed Cases of Cushing's Syndrome in Italy (2010-2023) 21
Figure 9: Diagnosed Cases of Cushing's Syndrome in Japan (2010-2023) 22
Figure 10: Levoketoconazole, Clinical Trials by Zone (%), 2016 32
Figure 11: Levoketoconazole, Clinical Trials by Trial status (%), 2016 33
Figure 12: LCI699 , Clinical Trials by Zone (%), 2016 35
Figure 13: LCI699, Clinical Trials by Trial status (%), 2016 36
Figure 14: Signifor LAR , Clinical Trials by Zone (%), 2016 39
Figure 15: Signifor LAR, Clinical Trials by Trial status (%), 2016 40
Figure 16: Metopirone, Clinical Trials by Trial status (%), 2016 42
Figure 17: Total Market Size of Cushing's Syndrome in USD, Million (2015) 43
Figure 18: Total Market Size of Cushing's Syndrome in USD, Million (2023) 44
Figure 19: United States Market Size of Cushing's Syndrome in USD, Million (2013-2023) 45
Figure 20: United Kingdom Market Size of Cushing's Syndrome in USD, Million (2013-2023) 46
Figure 21: Germany Market Size of Cushing's Syndrome in USD, Million (2013-2023) 47
Figure 22: France Market Size of Cushing's Syndrome in USD, Million (2013-2023) 48
Figure 23: Italy Market Size of Cushing's Syndrome in USD, Million (2013-2023) 49
Figure 24: Spain Market Size of Cushing's Syndrome in USD, Million (2013-2023) 50
Figure 25: Japan Market Size of Cushing's Syndrome in USD, Million (2013-2023)
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll